Truvy Boost Dietary Supplement Kit Recalled for Unapproved Ingredients
TruVision Health LLC is recalling Truvy Boost 30-Day Experience Kit (Lot 13993) because it contains DMHA and/or hordenine, which FDA has determined are not acceptable dietary ingredients.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Product contains DMHA and hordenine, which are risk-of-harm substances FDA has determined unacceptable for dietary supplements. While no illnesses have been reported in this recall, the ingredients pose inherent health risks.
Plain-English summary
TruVision Health LLC has recalled the Truvy Boost 30-Day Experience Kit due to the presence of DMHA and/or hordenine. The FDA has determined that these ingredients are not acceptable for use in dietary supplements.
The recalled product is the Truvy Boost 30-Day Experience Kit, Lot 13993. Approximately 22,125 packs were distributed in the United States and internationally to Australia, Canada, England, Germany, Ireland, and New Zealand.
Consumers who have purchased this product should discontinue use immediately. While no illnesses or injuries have been reported in association with this product, consumers with health concerns should consult their healthcare provider.
The recalled product
- Product
- Truvy Boost 30-Day Experience Kit
- Manufacturer
- TruVision Health LLC
- Category
- Drug — Dietary Supplement
- Hazard
- dmha
- hordenine
- unapproved-ingredient
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot 13993
Distribution
Distribution scope not specified by the agency.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27